HealingPreclinicalAnimal Studies

Pentadecapeptide

Also known as BPC-157 Full Sequence, Stable Gastric Pentadecapeptide

The full 15-amino acid sequence containing BPC-157, derived from gastric juice with comparable healing properties.

Preclinical - Same research base as BPC-157

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

250-500 mcg twice daily

Frequency

1-2x daily

Duration

4-12 weeks typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 250-500 mcg twice daily via Subcutaneous injection, 1-2x daily. Dose range: 250-500 mcg twice daily. Duration: 4-12 weeks typical.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 1-2x daily.

Mechanism of Action

Modulates the nitric oxide system, promotes angiogenesis, and accelerates tissue healing. Interacts with multiple growth factor systems and has cytoprotective effects on various tissues.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - Same research base as BPC-157.

Side Effects & Safety

Important Warnings

  • Caution with MCAS or histamine sensitivity
Nausea
dizziness
potential histamine release

References

No references available.